OBJECTIVE: To examine factors contributing to variance in functional outcome in first-episode psychosis (FEP) following 1 year of treatment. METHOD: Naturalistic 1-year follow-up of a FEP cohort (n = 200), from programs in four university centers in Ontario, Canada. Functional recovery was defined by 'Social and Occupational Functioning Assessment Scale' (SOFAS) score>60. Regression analysis examined the contribution of independent variables to variance in functional outcome. RESULTS: Twelve-month outcome measures were available for 76.5% of the original cohort. Of these, 70% reported being in school/work and in satisfactory relationships. The functional recovery rate was 51%, compared to 74% attaining symptomatic remission. The greatest contributors to variance in outcome were ongoing symptoms at 6 months and substance abuse comorbidity. CONCLUSION: After 1 year of treatment, FEP patients show high rates of symptomatic remission and relatively lower rates of functional recovery. Symptoms and substance abuse contribute to variance in outcome.
OBJECTIVE: To examine factors contributing to variance in functional outcome in first-episode psychosis (FEP) following 1 year of treatment. METHOD: Naturalistic 1-year follow-up of a FEP cohort (n = 200), from programs in four university centers in Ontario, Canada. Functional recovery was defined by 'Social and Occupational Functioning Assessment Scale' (SOFAS) score>60. Regression analysis examined the contribution of independent variables to variance in functional outcome. RESULTS: Twelve-month outcome measures were available for 76.5% of the original cohort. Of these, 70% reported being in school/work and in satisfactory relationships. The functional recovery rate was 51%, compared to 74% attaining symptomatic remission. The greatest contributors to variance in outcome were ongoing symptoms at 6 months and substance abuse comorbidity. CONCLUSION: After 1 year of treatment, FEP patients show high rates of symptomatic remission and relatively lower rates of functional recovery. Symptoms and substance abuse contribute to variance in outcome.
Authors: Sarah R Uzenoff; David L Penn; Karen A Graham; Sylvia Saade; Barbara B Smith; Diana O Perkins Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2012-01-26 Impact factor: 4.328
Authors: O Puig; R Penadés; I Baeza; V Sánchez-Gistau; E De la Serna; L Fonrodona; S Andrés-Perpiñá; M Bernardo; J Castro-Fornieles Journal: Eur Child Adolesc Psychiatry Date: 2012-02-22 Impact factor: 4.785
Authors: Ángel Del Rey-Mejías; David Fraguas; Covadonga M Díaz-Caneja; Laura Pina-Camacho; Josefina Castro-Fornieles; Inmaculada Baeza; Ana Espliego; Jessica Merchán-Naranjo; Ana González-Pinto; Elena de la Serna; Beatriz Payá; Montserrat Graell; Celso Arango; Mara Parellada Journal: Eur Child Adolesc Psychiatry Date: 2015-03-01 Impact factor: 4.785
Authors: Joseph Ventura; Kenneth L Subotnik; Lisa H Guzik; Gerhard S Hellemann; Michael J Gitlin; Rachel C Wood; Keith H Nuechterlein Journal: Schizophr Res Date: 2011-07-18 Impact factor: 4.939
Authors: Philippe Conus; Sue Cotton; Benno G Schimmelmann; Patrick D McGorry; Martin Lambert Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2017-05-05 Impact factor: 4.328